Latest Intelligence in Ireland

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

EU electricity: regional market merger will benefit Irish generators

The future merger of the Irish and British electricity markets is reliant upon the EU supporting a new Interconnector between Ireland and Wales. The merging of markets will have ramification for both countries, with the formerly isolated Irish generators facing future competition from the streamlined British utilities.

Published By Datamonitor
13 Mar 2006
CommentWire
CommentWire

ESB: an Anglo-Irish agreement

Increasing interconnection with the UK will bring further opportunities for ESB in the UK market, with the new contract with Smartest Energy the first steps towards this. An integrated UK-Ireland market will give ESB the opportunity to expand and manage its own portfolio more effectively across a larger market.

Published By Datamonitor
19 Apr 2006
CommentWire
CommentWire

ESB divestiture: too little too late

Ireland's incumbent power utility, ESB, has spent years trying to stave off a break-up. Together with the Irish Commission for Energy Regulation (CER), the company instituted a system of virtual power plant auctions to help Ireland comply with the letter of the EU Electricity Directive, if not the spirit. But it seems this will not be enough to prevent a new round of dramatic changes for ESB.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

ePower: rough ride for new entrant in Ireland

Published By Datamonitor
18 Jan 2001
CommentWire
CommentWire

Elan: trying to save a would-be blockbuster

The temporary suspension, on reports of worrying side effects, rocked shareholder confidence in Ireland's largest public company. Investors fear that one of Elan's two lead compounds may never generate revenue. The company may be able to save AN-1792, in which case it could still be a blockbuster drug - but the risks attached are high.

Published By Datamonitor
23 Jan 2002
CommentWire
CommentWire

Elan: to Genomics and Beyond

Published By Datamonitor
17 May 2001
CommentWire
CommentWire

Elan: taking the next step forward

Published By Datamonitor
26 Jul 2001
CommentWire
CommentWire

Elan: Antegren offers renewed hope for growth

Elan [ELN] and Biogen [BIIB] have announced that the Phase III maintenance trial of Antegren in Crohn's disease met the primary end-point of maintenance of response. The new data improves the chance of regulatory approval for Antegren, but the product may still need to find a role in inducing Crohn's disease remission to boost the fortunes of struggling Elan.

Published By Datamonitor
02 Feb 2004
CommentWire
CommentWire

Elan: AD vaccine gives new hope

Published By Datamonitor
07 Jun 2001
CommentWire
CommentWire

Elan/Biogen: MS players cower as Antegren looms

Shares of Biogen [BIIB] and Elan [ELN] jumped after they announced they would apply for FDA approval of Antegren for multiple sclerosis treatment ahead of schedule. Antegren is crucial for maintaining Biogen's market share as it is facing stiff competition from Serono's [SRA] Rebif in the US. The drug is equally vital to Elan, which in recent years has suffered numerous financial setbacks.

Published By Datamonitor
19 Feb 2004

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | » »|

No help is available.